U.S. FDA Approves Abecma for Triple-Class Exposed R/R Multiple Myeloma After Two Prior Lines of Therapy April 8, 2024
CARVYKTI® Approved by the U.S. FDA for Patients with R/R Multiple Myeloma Who Have Received at Least One Prior Line of Therapy April 8, 2024
NMPA approves IND application for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma April 2, 2024
FDA ODAC recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with R/R multiple myeloma March 26, 2024
Abecma (idecabtagene vicleucel) Approved in the European Union in Earlier Lines for Triple-Class Exposed R/R Multiple Myeloma March 26, 2024
FDA Advisory Committee Votes in Favor of Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy March 19, 2024
FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma March 19, 2024
Positive results announced from DREAMM-8 Ph 3 trial for Blenrep versus SoC combo in R/R multiple myeloma March 12, 2024
Application submitted to the EMA for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma March 12, 2024
Positive CHMP Opinion for CARVYKTI in Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma in Earlier Lines of Therapy March 5, 2024
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with R/R multiple myeloma February 26, 2024
DREAMM-7 Ph 3 trial shows Blenrep combination nearly tripled mPFS vs SOC combination in patients with R/R multiple myeloma February 26, 2024
Supplemental BLA submitted to US FDA seeking approval of DARZALEX FASPRO)-based regimen for treatment of patients with transplant-eligible, newly diagnosed multiple myeloma February 26, 2024
U.S. FDA ODAC Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study February 26, 2024
FDA accepted for Priority Review the BLA for linvoseltamab for R/R multiple myeloma that has progressed after at least three prior therapies February 26, 2024
Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed R/R Multiple Myeloma January 31, 2024
First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer January 18, 2024
EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep January 4, 2024
